GlassScriptPhysician profile
Wasif Hafeez
NPI 1245281435
$5,233.65
in general payments reported to CMS, 2019-2025
16 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 80% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $272 · 2021: $645 · 2022: $872 · 2023: $805 · 2024: $895 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,834.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,096.61 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $1,478.75 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Merck Sharp & Dohme LLC | $512.34 | 2020-2025 | Pifeltro, Delstrigo |
| Janssen Biotech, INC. | $417.94 | 2019-2023 | Symtuza |
| Janssen Products, LP | $195.91 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $124.74 | 2025 | Zenpep |
| Shionogi INC | $104.67 | 2024-2025 | Fetroja |
| Abbvie INC. | $89.86 | 2022-2025 | |
| Melinta Therapeutics, LLC | $42.64 | 2019-2024 | Kimyrsa, Rezzayo |
| Napo Pharmaceuticals INC | $34.73 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Axsome Therapeutics, INC. | $27.68 | 2024 | Auvelity |
| Theratechnologies INC. | $27.07 | 2025 | Egrifta, Trogarzo |
| Exact Sciences Corporation | $22.17 | 2024 | Cologuard Collection Kit |
| Janssen Scientific Affairs, LLC | $16.12 | 2023 | Symtuza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $13.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wasif Hafeez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.